Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.
Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.
Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.
Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.
Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”
Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”Close
Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.
Meg Heim named as its new Chief Executive Officer
Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.
Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.
Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”
Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”Close
Envision Pharma Group is pleased to announce the appointment of Meg Heim as its new Chief Executive Officer. Meg is an accomplished business leader with strong leadership experience, and an established reputation within Pharmaceutical, Medical Device and Health Technology markets. Throughout her career she has championed the professionalism of medical affairs and the innovations that improve patient experience.
Working closely with a strong and experienced Executive Leadership Team, Meg will be responsible for delivering an ambitious five-year plan that will reinforce Envision as the global leader in scientific and commercialization strategy and solutions; medical affairs; and lifecycle planning enabled by leading technology solutions and world-class people.
Meg joins Envision at a pivotal moment, with Group performance accelerating as it continues to deliver a compelling combination of technology and services to clients. Envision’s strategy and innovation has ensured the company continues to serve and anticipate its clients’ evolving needs. Meg replaces David Thompson, who steps down as CEO to pursue other opportunities, including in the not-for-profit sector at a cancer charity, after more than six years with Envision Pharma Group and over 25 years in the industry.
Brian Hepburn Executive Co-Chair of Envision Pharma Group said: “I am truly excited by the appointment of Meg as our new Chief Executive Officer. Meg has an established track record within the healthcare industry and brings with her a deep understanding of medical affairs which will be highly complementary to the existing expertise within the business. This is an exciting time for Envision as we continue to accelerate innovation and work towards our vision of improving lives through the power of our technology and expertise.”
Meg said: “I am energized to be joining Envision Pharma Group at such an important time in the industry. I see a clear opportunity for further growth building off established and new opportunities in the sector. The company has an exceptional team and client base, and I am looking forward to spending time with our people, our clients, and other key partners.”
Following the announcement in March of our Vitaccess partnership that is designed to power evidence generation for the biopharmaceutical industry, we are thrilled to be collaborating with Vitaccess on its “Keeping it real” webinar series.
On July 20, Envision’s Dawn Lobban, Global Lead, Patient Partnerships from Envision the Patient, will join Dr. Catherine Bottomley, Chief Scientific Officer from Vitaccess, to discuss patient engagement in the publication of real-world evidence (RWE). Secure your seat here in order to listen to two engaging and passionate speakers cover patient engagement and RWE.Close
Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules
Move combines Envision’s global leadership position in medical affairs communications with Vitaccess’ award-winning capabilities in real-world evidence (RWE)
Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) today announced Library, Datavision, and Scientific Communication Platform (SCP) modules will now feature Smart Citations from scite, an award-winning tool that helps students and researchers discover and understand research findings better.
Fully integrated into the publication details held within Library, Datavision, and SCP modules, Smart Citation badges provide regularly updated, at-a-glance views of how research has been cited and permits click-through access to the scite website for more detailed information on the article. This new functionality sits alongside and enhances the existing article-level metrics provided in iEnvision through integrations with Altmetric and Scopus.
Russell Traynor, Envision’s Global Head, iEnvision Platform Strategy, and former chair of the International Society of Medical Publication Professionals, said, “We are excited to announce this collaboration and hope that the addition of Smart Citations to Library, Datavision, and SCP will provide additional insights and value to the users of our solutions.”
Dr. Josh Nicholson, Chief Executive Officer of scite, added, “We’re very happy to be working with Envision to provide a powerful integration between the two platforms. Smart Citations are already used by various pharmaceutical companies and communications agencies and we’re happy to surface them in Library for a more streamlined workflow.”
Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com
scite is a Brooklyn-based start-up that helps researchers discover and evaluate scientific articles better through Smart Citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from around the world and is funded in part by the National Science Foundation and the National Institute of Drug Abuse of the National Institutes of Health. Learn more at: scite.ai
Library, built on the iEnvision medical project management platform, serves as a central repository for the enterprise-wide storage and sharing of final, approved scientific and medical materials such as publications and slide decks. Embedding Smart Citation in Library allows an at-a-glance view of the total number of times a paper has been cited and the context of these citations. Learn more at: www.envisionpharmagroup.com/technology/ienvision-library
The iEnvision Datavision module is designed to drive the compliant and efficient management of scientific and medical publications. With role-specific dashboards, publication managers can access the detailed information needed to start and manage publications. Containing built-in checklists and system validation, it ensures publications comply with Good Publication Practice and the International Committee of Medical Journal Editors (ICMJE) requirements. Learn more at: www.envisionpharmagroup.com/technology/datavision
iEnvision’s SCP is a centralized medical affairs solution, linking key scientific themes and statements to product-related assets such as publications, slides, and videos. The common template of SCP themes, key statements, and supporting statements maintains simple user navigation and a standardized approach to the formatting and development of SCPs – with a lexicon designed to ensure a consistent use of language that includes preferred and prohibited terms. Learn more at: www.envisionpharmagroup.com/technology/scientific-communication-platform-moduleClose
Leading global technology-enabled scientific communications company Envision Pharma Group has launched a suite of behavioral science-led solutions to expand the group’s capabilities and optimize value offering to its clients.
Envision the Change is spearheaded by Mark Lakeram (Global Lead, Behavioral Science) and supported by Directors Jenny Squibbs (in the UK) and Justine Swann (in the US). As a dedicated team of behavioral scientists, they understand that to affect real change the intricacies and realities of everyday life and health need to be considered.
Lakeram said, “All healthcare decisions are influenced by human behavior. By taking into account the science behind this, our proprietary Feel-Think-DoTM model helps to decode why people make the decisions they do. From strategic and tactical planning, to aiding information recall through data visualization and adult learning techniques – we provide counsel and support to drive behavior change that ultimately improves health outcomes.”
Susanne Clark, Head of Envision Scientific Solutions, added, “No matter what product challenges are ahead, understanding the behavior of key stakeholders will be paramount. I’m delighted that we’ve strengthened our service offering with Envision the Change in order to support our clients across all aspects of medical affairs and marketing, from planning to creative implementation for both external and internal audiences.”Close
Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) has announced a partnership with Vitaccess, an innovative research organization.
The Envision and Vitaccess partnership will bring a full-service, customizable approach to data gathering, insight generation, and scientific communications that will stand up to the nuances, scale, and challenges of any client setting.
Acknowledging that every client need is unique, this collaboration will help leverage patient-centric digital solutions to gather data quickly, flexibly, and at scale, and incorporate patients’ “lived experience” – insights which are often insufficiently integrated into the design and implementation of many RWE studies published globally.
The complexities in bringing a product to market cannot be underestimated. An increasing requirement for data leads to a growing need for more adaptive RWE research to be generated and communicated to regulators, pre and post approval. Envision and Vitaccess understand these additional demands placed on their biopharma clients, and the need to maximize value and access to their products through timely, insightful evidence generation which communicates the real-world impact of diseases and their treatments on patients.
Paul Archer, Envision Chief Commercial Strategy Officer, said, “This collaboration offers clients a really powerful toolbox to accelerate, scale, and publish their evidence-generation activities. We admire Vitaccess’ innovative, inclusive digital approach to designing patient-centric RWE studies, and whose flexible solutions provide access to outcomes measures that serve regulators, payers, and health systems all over the world.”
Dr. Mark Larkin, CEO and Founder of Vitaccess, commented, “Combining our Vitaccess Real™ real-time RWE platform and expertise in patient-centric research with Envision’s established leadership in medical affairs and communications brings clients a unique, full-service offering for engaging with patients and caregivers globally.”Close
Agency veteran Kate Paxton appointed to lead operation, bringing nearly 30 years of global and US biopharma experience
Leading global technology-enabled scientific communications company Envision Pharma Group has promoted Paul Archer to Chief Commercial Strategy Officer (CCSO).
In his new role, Archer will lead the development of an integrated commercial group strategy to drive continued revenue growth through service synergies and the implementation of new services. This is a newly defined position that reflects the continued expansion of Envision and its goals of being the global medical affairs partner of choice and to transform the pharma industry, ultimately leading to life-changing outcomes.
Working across the group, Archer will leverage Envision’s unique combination of technology and service capabilities to meet the evolving needs of its medical affairs clients and ensure it continues to lead the way in bringing innovative solutions to the market.
On his appointment that also sees Archer join Envision’s Executive Leadership Team, he said, “I am thrilled to be taking on this role. Envision is full of purpose-driven, talented people who thrive on delivering impactful, often award-winning work for our clients and their patients. I am genuinely excited to be able to apply my 20 years of strategic and commercial experience to drive a successful integrated commercial group for Envision and to realize the opportunities and value this creates for our clients, patients, talent, and Envision as a whole.”
David Thompson, CEO, Envision Pharma Group, added, “Paul has been a strong addition to Envision since he joined a year ago, and he will now lead a growing mandate as Chief Commercial Strategy Officer as we continue to exploit synergies across our four verticals of scientific services, technology, emerging biotech, and value – as well as uncover new service offerings through investment and acquisition that can help us improve our partnership strength with clients.”Close
Leading global technology-enabled scientific communications company Envision Pharma Group has appointed Julie Beeso as its Global Director, Professional Development and Engagement.
Having worked for almost 25 years across different medical communications roles in the UK and US, Julie’s extensive expertise will be used to develop, communicate, and execute a comprehensive professional development and talent management strategy for Envision Scientific Solutions (ESS) that supports progressive programs and engagement.
Starting out as a writer, Julie advanced to facilitating the account direction and team leadership for blockbuster launches in a previous role; overseeing new business activities; heading up a company division, and establishing a New York office. Julie joins Envision from Oxford PharmaGenesis where she helped to set up and lead its patient engagement specialty while also focusing on company-wide quality and training activities.
Alongside continuing to teach people how to be the best they can be in a competitive medcomms landscape, Julie’s responsibilities will cover ESS engagement and relations, talent placement and retention, alternative resourcing, and overseeing performance management.
Julie said, “I feel privileged to have the opportunity to work for Envision, whose reputation for integrity and quality – always alongside technological innovation – is second to none. Envision excels through its talented people. The company’s commitment to developing this talent is dynamic and inspiring, and I can’t wait to help take it to the next level!”
Susanne Clark, Global Head, Envision Scientific Services added, “We are thrilled to have Julie Beeso joining the team. With deep market insight and a unique skill set, Julie is ideally placed to meet the needs of a complex and rapidly evolving talent market. At Envision we have grown through continual innovation and improvement, and Julie will begin by scaling up our successful New Medical Writer program and elevating our entry talent offering. We are excited by this new chapter in our talent story.”Close
Global healthcare communications consultancy 90TEN, part of Envision Pharma Group, today announced its expansion to the US market and appointment of Kate Paxton as its US Head.
Paxton will oversee projects with a number of current 90TEN and Envision Pharma Group clients, grow her US team of healthcare communications specialists, leverage the existing rich resources within the organization for US client needs, and showcase the agency and its unique culture and approach.
“We are thrilled to have such an experienced and passionate professional like Kate join the growing 90TEN team,” said David Thompson, Chief Executive Officer, Envision Pharma Group. “Kate’s long history of building strategic and creative programs for healthcare clients of every size and scope – in addition to her deep understanding of how agencies grow and thrive – makes her ideally suited to lead 90TEN through this next, exciting phase.”
Paxton has almost 30 years of experience in agency communications and healthcare, ranging from corporate communications, product comms, and advocacy relations – to celebrity campaigns and issues management. Prior to 90TEN, Paxton spent a year and a half at JPA Health, where she designed and led campaigns for several biotech companies focused on oncology and rare diseases, and almost 23 years at Ketchum, where she held multiple leadership positions, including Managing Director of London Health for over 2 years and Practice Director of Washington, D.C. Health for over 7 years.
Campaigns that Paxton led have won multiple industry awards, including three Silver Anvils from the Public Relations Society of America and one Healthcare Campaign of the Year from PR Week.
“I have been an admirer of 90TEN for many years and always respected how bold, creative, and effective their campaigns are,” Paxton said. “So, when the opportunity came to lead the US launch and rollout, maximize the incredible talent and resources that already exist, and work with the award-winning London team – all of whom are passionate about changing lives for the better – I jumped at the chance.”
Based in London, 90TEN is one of the leading healthcare communications consultancies in Europe and works with half of the top 20 pharma companies in the world serving clients across Europe and North America. In 2020, it was named Communications Consultancy of the Year at both the Communiqué Awards and Sabre EMEA Awards. That same year, it became part of Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions.
Thompson added, “The US PR marketplace is highly competitive, but given the pairing of Envision’s footprint and deep scientific capabilities with 90TEN’s award-winning, behavioral science approach, we are confident that 90TEN US represents an exciting new offering for the American market.”Close
The partnership expands Two Labs’ suite of services and broadens its integration competency to include government price reporting
Acquisition follows increased investment in Envision from GHO Capital and its partners
Two Labs, an industry-leading pharma services company and part of Envision Pharma Group, today announced that it has acquired Riparian, a pharma consulting and SaaS company that helps manufacturers navigate pricing regulations, reporting, strategies, and program operations.
The acquisition expands Two Labs’ suite of pharma services, allowing the company to provide greater insights around the financials associated with launching and managing a drug, better positioning manufacturers for long-term success. Riparian’s deep understanding of government pricing regulations and program operations – combined with their consulting, business process outsourcing, and software capabilities – enables clients to better understand the financials of their drug, ensuring the prices reported to the government are in compliance with current government statutes and regulations.
“Government regulations and reporting requirements are growing increasingly complicated and it’s vital for both emerging and established manufacturers to work with an expert partner during this process,” said Howard Miller, CEO, Two Labs. “Riparian is a quickly growing, innovative company backed by a team of leading industry experts. It’s a privilege to have been selected as their partner by their leadership team.”
Riparian and Two Labs will work together to accelerate parent company, Envision Pharma Group’s US expansion plans in the emerging biotech pharma market. Envision acquired Two Labs in November 2020.
“This acquisition solidifies our vision to add Two Labs to the Envision family,” said David Thompson, CEO of Envision Pharma Group. “Bringing together Two Labs and Riparian reinforces Envision’s mission to invest in truly transformative organizations, and further expands our capabilities in improving patient access to life-changing medicines.”
“Like Two Labs, we’re committed to staying at the forefront of the evolving healthcare market, and we are excited for the growth we can experience by incorporating additional services and subject-matter expertise to meet evolving client needs,” said Riparian Co-Founder and CEO, David Chan. “This partnership elevates the work of both Two Labs and Riparian and creates significant growth potential.”
Riparian will continue operating out of their existing headquarters in Henderson, NV, with offices in Pasadena, CA and Johnson City, TN. Co-founders David Chan and Cynthia Hwang will remain with the company.Close
Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring.
doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today.
While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC.
Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi.
David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.”
“Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.”
Manish Goel, Global Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.”Close
Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.
The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues and geographies for Two Lab’s best-in-class launch planning services.
Two Labs, founded in 2003 and headquartered in Powell, Ohio, has offices and operations across the US and UK, and is an established strategic consulting and commercialization provider to the biopharma industry. Two Labs helps pharmaceutical companies develop and execute customized launch strategies for products. It has a proven track record of successful launches across all major therapeutic areas with unmatched client satisfaction.
Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide iEnvision® technology. A number of strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications have played an important role in its expansion.
David Thompson, CEO, Envision, said, “This exciting combination of Envision and Two Labs creates a compelling and unrivaled proposition in launch excellence partnership globally and in the US. We look forward to sharing our joint expertise and leveraging our complementary services across medical affairs and product launch planning to support our clients in their goal of bringing new medicines to market effectively and compliantly, to improve patient outcomes.”
Howard Miller, CEO, Two Labs, added, “We are delighted to be joining the Envision family and taking Two Labs to the next logical step in its successful journey to date. With Envision’s global footprint and Two Labs’ market-leading US footprint, we have a unique opportunity to enrich our client partnerships with more connected services across the launch continuum. The cultural fit between our organizations is compelling, and we look forward to a new chapter for Two Labs in partnering with David and the Envision team.”
The Partners at GHO commented, “We are glad to welcome Howard and the Two Labs team to the Envision Group. They have built a market-leading strategic consulting and commercialization business that in combination with Envision’s position as the ‘go-to’ tech-enabled scientific communications company will deliver major value to global pharma and biotech through a combined, unique launch excellence offering that accelerates and improves their route to market.”
Excellere Partners, a US-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, will exit its investment in Two Labs following a successful 4-year partnership.Close